Tonix Pharmaceuticals Holding Corp. (TNXP): Free Cash Flow
-$103.21M
Year ended 2025-12-31
-$158.11M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$103.21M | n/m | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | -$61.05M | n/m | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | -$109.90M | n/m | 2025-03-18, From 2023-01-01 |
| 2022-12-31 | -$146.20M | n/m | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | -$110.86M | n/m | 2023-03-13, From 2021-01-01 |
| 2020-12-31 | -$57.13M | n/m | 2022-03-14, From 2020-01-01 |
| 2019-12-31 | -$26.70M | n/m | 2021-03-15, From 2019-01-01 |
| 2018-12-31 | -$23.98M | n/m | 2020-03-24, From 2018-01-01 |
| 2017-12-31 | -$19.13M | n/m | 2019-03-18, From 2017-01-01 |
| 2016-12-31 | -$37.38M | n/a | 2018-03-09, From 2016-01-01 |
| No annual figure between 2012-12-31 and 2016-12-31. | |||
| 2012-12-31 | -$5.75M | n/m | 2014-03-28, From 2012-01-01 |
| 2011-12-31 | -$2.64M | n/m | 2013-11-22, From 2011-01-01 |
| 2010-12-31 | -$1.27M | n/a | 2012-03-30, From 2010-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | -$103.21M | n/m |
| Evommune, Inc. (EVMN) | 2025-12-31 | -$76.68M | n/m |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | -$516.0K | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | -$12.0K | n/m |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | -$63.51M | n/m |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | -$39.64M | n/m |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | -$56.37M | n/m |
| Jaguar Health, Inc. (JAGX) | 2024-12-31 | -$29.40M | n/a |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | -$72.45M | n/m |
Compare TNXP, EVMN, CVSI, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗